Patient-reported Outcomes and Adult Patients’ Disease Experience in the Idiopathic Inflammatory Myopathies. Report from the OMERACT 11 Myositis Special Interest Group

REFERENCES

1. 1.↵
   1. Khan S,
   2. Christopher-Stine L

   . Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am 2011;37:143–58.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Christopher-Stine L,
   2. Plotz PH

   . Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004;18:331–44.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Ponyi A,
   2. Borgulya G,
   3. Constantin T,
   4. Vancsa A,
   5. Gergely L,
   6. Danko K

   . Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology 2005;44:83–8.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Alexanderson H,
   2. Lundberg IE

   . Inflammatory muscle disease: clinical presentation and assessment of patients. Curr Rheumatol Rep 2007;9:273–9.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Miller FW,
   2. Rider LG,
   3. Chung YL,
   4. Cooper R,
   5. Danko K,
   6. Farewell V,
   7. et al.

   Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262–73.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Ware JE Jr.,
   2. Sherbourne CD

   . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Kirwan JR,
   2. Ahlmen M,
   3. de Wit M,
   4. Heiberg T,
   5. Hehir M,
   6. Hewlett S,
   7. et al.

   Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol 2005;32:2246–9.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Kirwan JR,
   2. Newman S,
   3. Tugwell PS,
   4. Wells GA,
   5. Hewlett S,
   6. Idzera L,
   7. et al.

   Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol 2009;36:2071–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Kirwan JR,
   2. Hewlett SE,
   3. Heiberg T,
   4. Hughes RA,
   5. Carr M,
   6. Hehir M,
   7. et al.

   Incorporating the patient perspective into outcome assessment in rheumatoid arthritis—progress at OMERACT 7. J Rheumatol 2005;32:2250–6.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Committee of Medicinal Products for Human Use. European Medicines Agency

    . Reflection Paper on the Regulatory Guidance for the Use of Health-related Quality of Life (HRQOL) Measures in the Evaluation of Medicinal Products, London, 27 July, 2005. [Internet. Accessed November 18, 2013.] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf
11. 11.↵
    1. US Food and Drug Administration

    . Guidance for Industry – patient-reported outcome measures: use in medical product development to support labeling claims. 2012 [Internet. Accessed November 18, 2013.] Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM183282.pdf).
12. 12.↵
    1. Critical Path Institute (cPATH)

    . Patient Reported Outcomes (PRO) Consortium. [Internet.] Available from://c-path.org/PRO.cfm).
13. 13.↵
    1. Stucki G,
    2. Kostanjsek N,
    3. Ustun B,
    4. Cieza A

    . ICF-based classification and measurement of functioning. Eur J Phys Rehabil Med 2008;44:315–28.

    OpenUrlPubMed
14. 14.↵
    1. Alemo Munters L,
    2. van Vollenhoven RF,
    3. Alexanderson H

    . Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis. ISRN Rheumatol 2011;2011:463124.

    OpenUrlPubMed
15. 15.↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR

    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Alexanderson H,
    2. Lundberg IE,
    3. Stenstrom CH

    . Development of the myositis activities profile—validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 2002;29:2386–92.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Bartlett SJ,
    2. Hewlett S,
    3. Bingham CO 3rd.,
    4. Woodworth TG,
    5. Alten R,
    6. Pohl C,
    7. et al.

    Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855–60.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Bingham CO 3rd.,
    2. Alten R,
    3. Bartlett SJ,
    4. Bykerk VP,
    5. Brooks PM,
    6. Choy E,
    7. et al.

    Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751–8.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Hewlett S,
    2. Sanderson T,
    3. May J,
    4. Alten R,
    5. Bingham CO 3rd.,
    6. Cross M,
    7. et al.

    ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology 2012;51:69–76.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Rider LG,
    2. Werth VP,
    3. Huber AM,
    4. Alexanderson H,
    5. Rao AP,
    6. Ruperto N,
    7. et al.

    Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/HAQ, Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 2011;63 Suppl 11:S118–57.

    OpenUrlCrossRef
21. 21.↵
    1. Boers M,
    2. Brooks P,
    3. Strand CV,
    4. Tugwell P

    . The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198–9.

    OpenUrlPubMed
22. 22.↵
    1. Hill C,
    2. Knox S,
    3. Thompson B,
    4. Williams E

    . Consensual qualitative research: an update. J Counsel Psychol 2005;52:196–205.

    OpenUrlCrossRef
23. 23.↵
    1. Cook KF,
    2. Bamer AM,
    3. Amtmann D,
    4. Molton IR,
    5. Jensen MP

    . Six patient-reported outcome measurement information system short form measures have negligible age- or diagnosis-related differential item functioning in individuals with disabilities. Arch Phys Med Rehabil 2012;93:1289–91.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Jackson CE,
    2. Barohn RJ,
    3. Gronseth G,
    4. Pandya S,
    5. Herbelin L; and
    6. Muscle Study Group

    . Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008;37:473–6.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Vincent KA,
    2. Carr AJ,
    3. Walburn J,
    4. Scott DL,
    5. Rose MR

    . Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051–7.

    OpenUrlCrossRef
26. 26.↵
    1. Landgraf J,
    2. Abetz L,
    3. Ware J

    . The CHQ users manual. 1st ed. Boston, MA: The Health Institute; 1996.
27. 27.↵
    1. Huber AM,
    2. Hicks JE,
    3. Lachenbruch PA,
    4. Perez MD,
    5. Zemel SL,
    6. Rennebohm RM,
    7. et al.

    Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001;28:1106–11.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Dalakas MC,
    2. Sonies B,
    3. Dambrosia J,
    4. Sekul E,
    5. Cupler E,
    6. Sivakumar K

    . Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712–6.

    OpenUrlCrossRef
29. 29.↵
    The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I–II Study Group. Arch Neurol 1996;53:141–7.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Mahoney FI,
    2. Barthel DW

    . Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–5.

    OpenUrlPubMed
31. 31.↵
    1. Munro BH

    . Statistical methods for health care research. 3rd ed. Philadelphia: Lippincott;1997:235.
32. 32.↵
    1. Nunnally J

    . Psychometric theory. New York: McGraw-Hill; 1978.
33. 33.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Alexanderson H,
    2. Reed AM,
    3. Ytterberg SR

    . The Myositis Activities Profile - initial validation for assessment of polymyositis/dermatomyositis in the USA. J Rheumatol 2012;39:2134–41.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Tugwell P,
    2. Bombardier C,
    3. Buchanan WW,
    4. Goldsmith CH,
    5. Grace E,
    6. Hanna B

    . The MACTAR Patient Preference Disability Questionnaire—an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987;14:446–51.

    OpenUrlPubMed
36. 36.↵
    1. Mouthon L,
    2. Rannou F,
    3. Bérezné A,
    4. Pagnoux C,
    5. Guilpain P,
    6. Goldwasser F,
    7. et al.

    Patient preference disability questionnaire in systemic sclerosis: a cross-sectional survey. Arthritis Rheum 2008;59:968–73.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Verhoeven AC,
    2. Boers M,
    3. van der Liden S

    . Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. J Rheumatol 2000;27:2801–9.

    OpenUrlPubMed
38. 38.↵
    1. Guillemin F

    . Cross-cultural adaptation and validation of health status measures. Scand J Rheumatol 1995;24:61–3.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Alemo Munters L,
    2. Dastmalchi M,
    3. Andgren V,
    4. Emilsson C,
    5. Bergegård J,
    6. Regardt M,
    7. et al.

    Endurance exercise improves health and may reduce disease activity in patients with established polymyositis and dermatomyositis. A multicenter randomized controlled trial with a 1-year open extension follow-up. Arthritis Care Res 2013; July 16. [E-pub ahead of print]
40. 40.↵
    1. World Health Organization

    . International Classification of Functioning, Disability and Health (ICF). [Internet. Accessed November 18, 2013.] Available from: http://www.who.int/classifications/icf/en/
41. 41.↵
    1. Meenan RF,
    2. Mason JH,
    3. Anderson JJ,
    4. Guccione AA,
    5. Kazis LE

    . AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales. Arthritis Rheum 1992;35:1–10.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Josefson A,
    2. Romanus E,
    3. Carlsson J

    . A functional index in myositis. J Rheumatol 1996;23:1380–4.

    OpenUrlPubMed
43. 43.↵
    1. Rider LG,
    2. Kozio D,
    3. Giannini EH,
    4. Jain MS,
    5. Smith MR,
    6. Whitney-Mahoney K,
    7. et al.

    Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465–72.

    OpenUrlCrossRef
44. 44.↵
    1. Alexanderson H,
    2. Broman L,
    3. Tollbäck A,
    4. Josefson A,
    5. Lundberg IE,
    6. Stenström CH

    . Functional Index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006;55:114–22.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Alexanderson H,
    2. Dastmalchi M,
    3. Esbjörnsson-Liljedahl M,
    4. Opava CH,
    5. Lundberg IE

    . Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007;57:768–77.

    OpenUrlCrossRefPubMed
46. 46.↵
    1. Ghazi E,
    2. Kling MA,
    3. Propart K,
    4. Okawa J,
    5. Werth VP

    . Increased depression and anxiety symptoms in a group of dermatomyositis patients [abstract]. Arthritis Rheum 2011;63 Suppl 10:S92.

    OpenUrl
47. 47.↵
    1. Campbell RCJ,
    2. Scott DL,
    3. Kiely PD,
    4. Gordon P

    . Fatigue in idiopathic inflammatory myopathies (IIM): Prevalence, impact and association with quality of life [abstract]. Arthritis Rheum 2011;63 Suppl:S89.

    OpenUrl
48. 48.↵
    1. Campbell RCJ,
    2. Scott DL,
    3. Kiely PD,
    4. Gordon P

    . Predictors of experienced fatigue in idiopathic inflammatory myopathy (IIM): Psychological factors and pain are more predictive than disease activity, damage or strength [abstract]. Arthritis Rheum 2011;63 Suppl:S90.

    OpenUrl
49. 49.
    1. Sultan SM,
    2. Ioannou Y,
    3. Moss K,
    4. Isenberg DA

    . Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002;41:22–6.

    OpenUrlAbstract/FREE Full Text
50. 50.
    1. Regardt M,
    2. Welin Henriksson E,
    3. Alexanderson H,
    4. Lundberg IE

    . Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology 2011;50:578–85.

    OpenUrlAbstract/FREE Full Text
51. 51.
    1. Alexanderson H,
    2. Stenstrom CH,
    3. Lundberg I

    . Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 1999;38:608–11.

    OpenUrlAbstract/FREE Full Text
52. 52.
    1. Alexanderson H,
    2. Stenstrom CH,
    3. Jenner G,
    4. Lundberg I

    . The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000;29:295–301.

    OpenUrlCrossRefPubMed
53. 53.
    1. Sadjadi R,
    2. Rose MR; and
    3. Muscle Study Group

    . What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry 2010;81:1164–6.

    OpenUrlAbstract/FREE Full Text
54. 54.
    1. Vojinović J,
    2. Riley P,
    3. Maillard S,
    4. Pilkington C

    . Importance of aggressive treatment in juvenile dermatomyositis [Serbian]. Srp Arh Celok Lek 2005;133 Suppl 2:118–23.

    OpenUrlPubMed
55. 55.
    1. Apaz MT,
    2. Saad-Magalhaes C,
    3. Pistorio A,
    4. Ravelli A,
    5. de Oliveira Sato J,
    6. Marcantoni MB,
    7. et al.

    Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009;61:509–17.

    OpenUrlCrossRefPubMed
56. 56.
    1. Hunt SM,
    2. McKenna SP,
    3. McEwen J,
    4. Williams J,
    5. Papp E

    . The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med A 1981;15:221–9.

    OpenUrlPubMed
57. 57.
    1. Chung YL,
    2. Mitchell HL,
    3. Houssien DA,
    4. Al-Mahrouki H,
    5. Carr AJ,
    6. Scott DL

    . A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile. Clin Exp Rheumatol 2001;19:447–50.

    OpenUrlPubMed
58. 58.
    1. Varni JW

    . The PedsQL measurement model for the Pediatric Quality of Life Inventory. [Internet. Accessed November 18, 2013.] Available from: http://www.pedsql.org/
59. 59.
    1. Butbul Aviel Y,
    2. Stremler R,
    3. Benseler SM,
    4. Cameron B,
    5. Laxer RM,
    6. Osa S,
    7. et al.

    Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. Rheumatology 2011;50:2051–60.

    OpenUrlAbstract/FREE Full Text
60. 60.
    1. Sansone VA,
    2. Panzeri M,
    3. Montanari M,
    4. Apolone G,
    5. Gandossini S,
    6. Rose MR,
    7. et al.

    Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol 2010;17:1178–87.

    OpenUrlCrossRefPubMed
61. 61.
    1. Sadjadi R,
    2. Vincent KA,
    3. Carr AJ,
    4. Walburn J,
    5. Brooks VL,
    6. Pandya S,
    7. et al.

    Validation of the individualized neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in the USA versus UK. Health Qual Life Outcomes 2011;9:114.

    OpenUrlCrossRefPubMed
62. 62.
    1. Muscle Study Group

    . Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718–20.

    OpenUrlCrossRef
63. 63.
    1. Rider LG,
    2. Feldman BM,
    3. Perez MD,
    4. Rennebohm RM,
    5. Lindsley CB,
    6. Zemel LS,
    7. et al.

    Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997;40:1976–83.

    OpenUrlCrossRefPubMed
64. 64.
    1. Rider LG,
    2. Giannini EH,
    3. Harris-Love M,
    4. Joe G,
    5. Isenberg D,
    6. Pilkington C,
    7. et al.

    Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603–17.

    OpenUrlAbstract/FREE Full Text
65. 65.
    1. Chung L,
    2. Genovese MC,
    3. Fiorentino DF

    . A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763–7.

    OpenUrlCrossRefPubMed
66. 66.
    1. Ruperto N,
    2. Ravelli A,
    3. Pistorio A,
    4. Ferriani V,
    5. Calvo I,
    6. Ganser G,
    7. et al.

    The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4–13.

    OpenUrlCrossRefPubMed
67. 67.
    1. Neri R,
    2. Mosca M,
    3. Stampacchia G,
    4. Vesprini E,
    5. Tavoni A,
    6. d’Ascanio D,
    7. et al.

    Functional and isokinetic assessment of muscle strength in patients with idiopathic inflammatory myopathies. Autoimmunity 2006;39:255–9.

    OpenUrlCrossRefPubMed
68. 68.
    1. Muscle Study Group

    . A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70:427–36.

    OpenUrlCrossRefPubMed
69. 69.
    1. Chen YJ,
    2. Wu CY,
    3. Shen JL

    . Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 2007;87:33–8.

    OpenUrlCrossRefPubMed
70. 70.
    1. Saito E,
    2. Koike T,
    3. Hashimoto H,
    4. Miyasaka N,
    5. Ikeda Y,
    6. Hara M,
    7. et al.

    Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2008;18:34–44.

    OpenUrlCrossRefPubMed
71. 71.
    1. Sanner H,
    2. Gran JT,
    3. Sjaastad I,
    4. Flato B

    . Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology 2009;48:1541–7.

    OpenUrlAbstract/FREE Full Text
72. 72.
    1. Varju C,
    2. Petho E,
    3. Kutas R,
    4. Czirjak L

    . The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003;17:83–7.

    OpenUrlAbstract/FREE Full Text
73. 73.
    1. Feldman BM,
    2. Ayling-Campos A,
    3. Luy L,
    4. Stevens D,
    5. Silverman ED,
    6. Laxer RM

    . Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995;22:326–31.

    OpenUrlPubMed
74. 74.
    1. Takken T,
    2. Elst E,
    3. Spermon N,
    4. Helders PJ,
    5. Prakken AB,
    6. van der Net J

    . The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. Rheumatology 2003;42:591–5.

    OpenUrlAbstract/FREE Full Text
75. 75.
    1. McCann LJ,
    2. Juggins AD,
    3. Maillard SM,
    4. Wedderburn LR,
    5. Davidson JE,
    6. Murray KJ,
    7. et al.

    The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology 2006;45:1255–60.

    OpenUrlAbstract/FREE Full Text
76. 76.
    1. Ramanan AV,
    2. Campbell-Webster N,
    3. Ota S,
    4. Parker S,
    5. Tran D,
    6. Tyrrell PN,
    7. et al.

    The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570–8.

    OpenUrlCrossRefPubMed
77. 77.
    1. Ravelli A,
    2. Trail L,
    3. Ferrari C,
    4. Ruperto N,
    5. Pistorio A,
    6. Pilkington C,
    7. et al.

    Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63–72.

    OpenUrlCrossRef
78. 78.
    1. Fix AJ,
    2. Daughton D

    . Human activity profile professional manual. Odessa, Florida: Psychological Assessment Resources, Inc.; 1988.
79. 79.
    1. Matsunaga S,
    2. Sakou T,
    3. Onishi T,
    4. Hayashi K,
    5. Taketomi E,
    6. Sunahara N,
    7. et al.

    Prognosis of patients with upper cervical lesions caused by rheumatoid arthritis: comparison of occipitocervical fusion between c1 laminectomy and nonsurgical management. Spine 2003;28:1581–7.

    OpenUrlCrossRefPubMed
80. 80.
    1. Weinstein AA,
    2. Drinkard BM,
    3. Diao G,
    4. Furst G,
    5. Dale JK,
    6. Straus SE,
    7. et al.

    Exploratory analysis of the relationships between aerobic capacity and self-reported fatigue in patients with rheumatoid arthritis, polymyositis, and chronic fatigue syndrome. PM R 2009;1:620–8.

    OpenUrlCrossRefPubMed
81. 81.
    1. Walter MC,
    2. Lochmuller H,
    3. Toepfer M,
    4. Schlotter B,
    5. Reilich P,
    6. Schröder M,
    7. et al.

    High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22–8.

    OpenUrlCrossRefPubMed
82. 82.
    1. Soueidan SA,
    2. Dalakas MC

    . Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876–9.

    OpenUrlCrossRef
83. 83.
    1. van de Vlekkert J,
    2. Hoogendijk JE,
    3. de Haan RJ,
    4. Algra A,
    5. van der Tweel I,
    6. van der Pol WL,
    7. et al.

    Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010;20:382–9.

    OpenUrlCrossRefPubMed
84. 84.
    1. Sancricca C,
    2. Mora M,
    3. Ricci E,
    4. Tonali PA,
    5. Mantegazza R,
    6. Mirabella M

    . Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011;32:841–7.

    OpenUrlCrossRefPubMed
85. 85.
    1. Convery FR,
    2. Minteer MA,
    3. Amiel D,
    4. Connett KL

    . Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1977;58:494–9.

    OpenUrlPubMed
86. 86.
    1. Miller FW,
    2. Leitman SF,
    3. Cronin ME,
    4. Hicks JE,
    5. Leff RL,
    6. Wesley R,
    7. et al.

    Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380–4.

    OpenUrlCrossRefPubMed
87. 87.
    1. Villalba L,
    2. Hicks JE,
    3. Adams EM,
    4. Sherman JB,
    5. Gourley MF,
    6. Leff RL,
    7. et al.

    Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392–9.

    OpenUrlCrossRefPubMed
88. 88.
    1. Dalakas MC,
    2. Illa I,
    3. Dambrosia JM,
    4. Soueidan SA,
    5. Stein DP,
    6. Otero C,
    7. et al.

    A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993–2000.

    OpenUrlCrossRefPubMed
89. 89.
    1. Melzack R

    . The short-form McGill Pain Questionnaire. Pain 1987;30:191–7.

    OpenUrlCrossRefPubMed
90. 90.
    1. Chalder T,
    2. Berelowitz G,
    3. Pawlikowska T,
    4. Watts L,
    5. Wessely S,
    6. Wright D,
    7. et al.

    Development of a fatigue scale. J Psychosom Res 1993;37:147–53.

    OpenUrlCrossRefPubMed
91. 91.
    1. Belza BL,
    2. Henke CJ,
    3. Yelin EH,
    4. Epstein WV,
    5. Gilliss CL

    . Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93–9.

    OpenUrlPubMed
92. 92.
    1. McNair DM,
    2. Lorr M,
    3. Droppleman LF

    . Manual for the profile of mood states. San Diego: Educational and Industrial Testing Service; 1971.